Amgen Inc.
Long

FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients

58
AMGN: Amgen
2018-12-14 16:00:00
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.